Primary Ovarian Insufficiency Market Report 2026

The primary ovarian insufficiency market size has grown strongly in recent years. It will grow from $1.18 billion in 2025 to $1.3 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increasing awareness of female reproductive health, wider use of hormone replacement therapy, growth in infertility treatment demand, improved diagnostic capabilities for hormonal disorders, expansion of specialty fertility clinics.

The primary ovarian insufficiency market size is expected to see strong growth in the next few years. It will grow to $1.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing investment in regenerative medicine research, rising demand for early diagnosis solutions, expansion of precision medicine approaches, growing focus on non-invasive fertility treatments, increasing availability of advanced reproductive technologies. Major trends in the forecast period include increasing adoption of personalized hormone therapies, rising use of advanced diagnostic testing, growing focus on fertility preservation solutions, expansion of regenerative and stem cell-based treatments, enhanced integration of multidisciplinary care models.

The rising prevalence of autoimmune disorders is expected to drive the growth of the primary ovarian insufficiency market in the coming years. Autoimmune disorders are a group of conditions in which the immune system mistakenly attacks and damages the body’s own healthy cells and tissues. The increasing occurrence of autoimmune disorders is largely attributed to genetic predisposition, where individuals inherit specific genes that make them more vulnerable to immune system dysfunction. Primary ovarian insufficiency (POI) helps in understanding autoimmune disorders by illustrating how hormonal imbalances and immune system dysregulation interact, resulting in an increased risk of autoimmune conditions among affected individuals. For instance, in 2025, according to WeCovr, a UK-based embedded insurance platform, it is estimated that more than 3.5 million people in the United Kingdom will be living with an autoimmune disease by the end of 2025, reflecting an increase of nearly 40% since the early 2000s and exceeding earlier estimates of 3% to 9%. Therefore, the growing prevalence of autoimmune disorders is driving the expansion of the primary ovarian insufficiency market.

The increasing focus on preventive care is expected to further propel the growth of the primary ovarian insufficiency market going forward. Preventive care includes healthcare services and interventions aimed at disease prevention, early detection of health conditions, and the promotion of overall health and well-being. The emphasis on preventive care is rising due to greater awareness of the benefits of early diagnosis, which helps minimize severe health complications and reduce long-term healthcare costs. Primary ovarian insufficiency (POI) supports this preventive approach by emphasizing the importance of early screening, timely intervention, and fertility preservation to lower long-term health risks in affected women. For instance, in March 2024, according to a report by the Government of the United Kingdom, a UK-based information website, the proportion of people with type 1 diabetes in England receiving all eight care processes at GP practices participating in the NDA increased to 43.8% in March 2023, up from 35.2% the previous year. Therefore, the growing emphasis on preventive care is contributing to the growth of the primary ovarian insufficiency market.

In July 2023, EQT Private Capital Asia, a China-based investment company, acquired a 60% stake in Indira IVF Hospital Pvt. Ltd. for $1.1 billion. Through this acquisition, EQT Private Capital Asia aims to strengthen Indira IVF’s market leadership across India and Asia, improve its technological capabilities, and scale its operations to take advantage of the rapidly expanding fertility services market. Indira IVF Hospital Pvt. Ltd. is an India-based fertility clinic that offers specialized diagnosis and treatment for primary ovarian insufficiency (POI), also referred to as premature ovarian failure (POF).

Major companies operating in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals AS, PreventionGenetics LLC, The Fertility Partnership UK, Celmatix Inc, IVIRMA Global, Bioscience Institute SpA, Sparsh Diagnostics Pvt Ltd, Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty Ltd, OvaScience Inc, Merck KGaA, Roche Holding AG, Pfizer Inc, Novartis AG, AbbVie Inc, Eli Lilly And Company, Bayer AG, Takeda Pharmaceutical Company Limited.

North America was the largest region in the primary ovarian insufficiency market in 2025. The regions covered in the primary ovarian insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary ovarian insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the primary ovarian insufficiency market by increasing costs of imported diagnostic kits, hormone formulations, laboratory equipment, and specialized medical devices used in diagnosis and treatment. Healthcare providers in North America and Europe are most affected due to dependence on imported pharmaceuticals and diagnostic technologies, while Asia-Pacific faces higher costs for advanced fertility treatment inputs. These tariffs are contributing to higher treatment expenses and slower adoption of advanced therapies. However, they are also encouraging local manufacturing of diagnostics, regional pharmaceutical production, and increased investment in domestic reproductive health research capabilities.

The primary ovarian insufficiency market research report is one of a series of new reports that provides primary ovarian insufficiency market statistics, including primary ovarian insufficiency industry global market size, regional shares, competitors with a primary ovarian insufficiency market share, detailed primary ovarian insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the primary ovarian insufficiency industry. This primary ovarian insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary ovarian insufficiency (POI) is a condition in which the ovaries cease to function properly before the age of 40, resulting in decreased estrogen levels and irregular or absent menstrual cycles. This condition can lead to infertility and is frequently linked to hormonal imbalances, even though some level of ovarian activity may still be present.

The primary treatment types for primary ovarian insufficiency include hormone replacement therapy (HRT), calcium and vitamin D supplementation, in vitro fertilization (IVF), stem cell therapy, and other approaches. Hormone replacement therapy (HRT) involves the medical administration of hormones, usually estrogen and progesterone, to relieve symptoms caused by hormonal deficiencies or imbalances, particularly those associated with menopause. Diagnostic techniques include blood testing, ultrasound imaging, and genetic testing. This condition may affect individuals across various age groups, including under 20 years, 20 to 30 years, 30 to 45 years, and over 45 years, and services are provided through end users such as hospitals, clinics, and specialized fertility centers.

The primary ovarian insufficiency market consists of revenues earned by entities by providing services such as fertility treatments, diagnostic and genetic testing services, osteoporosis management services, and endocrinology consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ovarian insufficiency market also consists of sales of products including genetic testing kits, bone health supplements, psychological and supportive care products, testosterone therapy, and antioxidant supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.